Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, Masliah E. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci. 2005 Oct;8(10):1343-9. PubMed Abstract

REAGENTS/MATERIAL:

Western blots were probed with a monoclonal antibody against Ab (6E10, 1:1,000; Signet Laboratories)or antibodies against BACE1 (1:1,000; ProSci) and APP CTFs (1:5,000; provided by E. Koo, University of California San Diego)or BACE1 antibody (1:1,000; ProSci).

For Immunocytochemistry fixed brains were stained with antibodies against Ab (4G8, 1:2,000; Signet Laboratories), APP CTFs (1:5,000; CT-15, gift of E. Koo, University of California San Diego), MAP2 (1:50, Chemicon) or synaptophysin. To measure BACE1 expression, sections were immunolabeled with a rabbit polyclonal antibody (BACE1, 1:500, ProSci) and developed with diaminobenzidine (DAB).